Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis J Montaner

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Journal of Leukocyte Biology|February 11, 2018
Transition in JLB Leadership: Letter from the new Editor-in-ChiefLuis J Montaner
Clinics in Laboratory Medicine|September 25, 2002
Immune reconstitutionDrew Weissman, Luis J Montaner
Journal of Leukocyte Biology|April 2, 2011
Editorial: Is HIV-1 induction of macrophage expression of PD-L1 and PD-L2 its weakest or strongest link to disease? HIV-1 plays both sides by augmenting and limiting T cell activation to survive in vivoSean C Patro, Luis J Montaner
Journal of Immunology (Baltimore, Md. : 1950)|September 19, 2025
Evolving the cutting edge: enhancing author flexibility and elevating peer recognitionLuis J Montaner, Gail A Bishop
The Journal of Infectious Diseases|May 19, 2017
Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus ReservoirJames L Riley, Luis J Montaner
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 24, 2020
Correction to: Effect of Opioid Use on Immune Activation and HIV Persistence on ARTLivio Azzoni, David Metzger, Luis J Montaner
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|September 25, 2020
Effect of Opioid Use on Immune Activation and HIV Persistence on ARTLivio Azzoni, David Metzger, Luis J Montaner
AIDS (London, England)|September 16, 2015
Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2DCostin Tomescu, Domenico Mavilio, Luis J Montaner
Current HIV Research|March 30, 2004
Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparingLivio Azzoni, Emmanouil Papasavvas, Luis J Montaner
AIDS (London, England)|February 23, 2017
IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulationCostin Tomescu, Pablo Tebas, Luis J Montaner
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Journal of Leukocyte Biology|February 11, 2018
Transition in JLB Leadership: Letter from the new Editor-in-ChiefLuis J Montaner
Clinics in Laboratory Medicine|September 25, 2002
Immune reconstitutionDrew Weissman, Luis J Montaner
Journal of Leukocyte Biology|April 2, 2011
Editorial: Is HIV-1 induction of macrophage expression of PD-L1 and PD-L2 its weakest or strongest link to disease? HIV-1 plays both sides by augmenting and limiting T cell activation to survive in vivoSean C Patro, Luis J Montaner
Journal of Immunology (Baltimore, Md. : 1950)|September 19, 2025
Evolving the cutting edge: enhancing author flexibility and elevating peer recognitionLuis J Montaner, Gail A Bishop
The Journal of Infectious Diseases|May 19, 2017
Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus ReservoirJames L Riley, Luis J Montaner
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 24, 2020
Correction to: Effect of Opioid Use on Immune Activation and HIV Persistence on ARTLivio Azzoni, David Metzger, Luis J Montaner
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|September 25, 2020
Effect of Opioid Use on Immune Activation and HIV Persistence on ARTLivio Azzoni, David Metzger, Luis J Montaner
AIDS (London, England)|September 16, 2015
Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2DCostin Tomescu, Domenico Mavilio, Luis J Montaner
Current HIV Research|March 30, 2004
Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparingLivio Azzoni, Emmanouil Papasavvas, Luis J Montaner
AIDS (London, England)|February 23, 2017
IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulationCostin Tomescu, Pablo Tebas, Luis J Montaner
Pageof 19